Luís Pereira de Almeida has been working since 1998 in gene/molecular therapy approaches for the Central Nervous System. In 2002 published one of the first papers showing that lentiviral vectors can be used to produce in vivo models of neurodegenerative diseases (e.g. Huntington's, Parkinson's, Machado-Joseph's disease), an approach on which his group specialized and that is now extensively used in the field (de Almeida LP et al The Journal of Neuroscience 2002). Professor at the Faculty of Pharmacy, University of Coimbra since 2003, coordinated the Masters in Pharmaceutical Biotechnology and the Doctoral Programme in Experimental Biology and Biomedicine, and teaches at graduate and undergraduate levels. His research activity is developed at CNC - Center for Neuroscience and Cell Biology of the University of Coimbra (Group Leader and President), and CIBB - Center for Innovative Biomedicine and Biotechnology (Coordinator). He spent short sabbatical leaves at CEA, Saclay in France (2005) and at the Massachussetts Institute of Technology (2010). The research of his group has been focused on molecular approaches for the study of the molecular mechanisms and advanced therapies for neurodegenerative disorders with a focus on Machado-Joseph disease/spinocerebellar ataxia type 3, including disease modifying and gene silencing approaches, autophagy activation and proteolysis inhibition, sirtuin-1 activation, etc, works published in over 100 papers and book chapters cited over thirteen thousand times, in journals such as Brain (5), Nature Communications, Cell Metabolism, Cell Reports, Acta Neuropathologica, Annals of Neurology, Human Molecular Genetics (6), Scientific Reports, PlosOne, awarded with prizes by Janssen Pharmaceutics, the Portuguese Society for Neurosciences (2009, 2011, 2012, 2013), the Portuguese Society of Human Genetics (2009), and Fundação Pulido Valente. Luis Pereira de Almeida has mentored 12 pos doctoral fellows and >20 PhD students and is or has been responsible for over 30 research projects funded by the Portuguese Foundation for Science and Technology, the Association Française de Myopathies, private funds, the National Ataxia Foundation (USA), the Center Region of Portugal and led one of the twelve European research groups that constitute the Marie Curie Initial Training Network “TreatPolyQ” within the 7th Framework Program of the European Union. His group integrates(ed) an iMi (EU Innovative Medicines Initiative) Project (Accelerating Research and Development in Advanced Therapies - ARDAT), an E-rare Eranet and 3 JPND european network projects, 2 of these - SynSpread and ModelPolyQ under his coordination. Bibliometric indicators: Publications: Books and book chapters : 9; Peer-reviewed papers: >100; Other: 43; Total 145; Publications Q1: 85%; Publications in Top 10%: 21; Conferences by invitation: >200; Communications in conferences by abstract submission: >300; PhD Thesis Commitees: 72; Principal opponent: 25; Citation Number (Google scholar): 13,000; h-index (Google scholar): 46; Atracted funding as PI: > 5 000 000; Evaluation by University of Coimbra (Research, Teaching, Technology transfer, University Management): (2014-2016) - Excelent. (2011-2013) - Excelent. Supervised 17 pos doctoral fellows, Supervised >20 PhD Students.

Identificação pessoal

Nome completo

Nomes de citação

  • Pereira de Almeida, Luis
  • de Almeida, L
  • Almeida, L
  • Pereira de Almeida, L

Identificadores de autor

Ciência ID
Google Scholar ID
Researcher Id
Scopus Author Id

Endereços de correio eletrónico

  • luispa@cnc.uc.pt (Profissional)
  • luispa@ci.uc.pt (Profissional)
  • luispa@ff.uc.pt (Profissional)


  • University of Coimbra | Center for Neuroscience and Cell Biology | Rua Larga, 3004-504, Coimbra, Coimbra, Portugal (Profissional)


  • https://cibb.uc.pt/research/innovative-therapies/vectors-gene-cell-therapy/ (Profissional)
  • https://cnc.uc.pt/en/research-group/gene-and-stem-cell-therapies-for-the-brain (Profissional)

Domínios de atuação

  • Ciências Médicas e da Saúde - Biotecnologia Médica - Diagnóstico e Terapias de Base Genética
  • Ciências Médicas e da Saúde - Biotecnologia Médica - Biotecnologia Aplicada à Saúde
  • Ciências Médicas e da Saúde - Medicina Básica - Neurociências
  • Ciências Médicas e da Saúde - Biotecnologia Médica - Tecnologias que envolvem a Manipulação de Células,Tecidos,Órgãos ou todo o Organismo
  • Ciências Médicas e da Saúde - Medicina Clínica - Neurologia Clínica
  • Ciências Médicas e da Saúde - Medicina Básica - Genética Humana
  • Ciências da Engenharia e Tecnologias - Nanotecnologia
  • Ciências Médicas e da Saúde - Medicina Básica - Farmacologia e Farmácia
  • Ciências Médicas e da Saúde - Outras Ciências Médicas
  • Ciências Naturais - Ciências Biológicas
  • Ciências Médicas e da Saúde - Ciências da Saúde
  • Ciências Naturais - Ciências Biológicas - Biologia Molecular
  • Ciências Naturais - Ciências Biológicas - Biologia Celular


Idioma Conversação Leitura Escrita Compreensão Peer-review
Português Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2)
Francês Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2)
Inglês Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2)
Espanhol; Castelhano Utilizador elementar (A1) Utilizador independente (B1) Utilizador elementar (A1) Utilizador elementar (A1) Utilizador elementar (A1)
Percurso profissional


Categoria Profissional
Instituição de acolhimento
2019 - Atual Investigador Coordenador (carreira) (Investigação) CIBB - Center for Innovative Biomedicine and Biotecnology - Associated Laboratory, Portugal
CIBB - Center for Innovative Biomedicine and Biotecnology - Associated Laboratory, Portugal
1998/01/01 - 2001/04/03 Estagiário de Investigação (Investigação) Centre Hospitalier Universitaire Vaudois, Suiça

Docência no Ensino Superior

Categoria Profissional
Instituição de acolhimento
2020/06 - Atual Professor Associado (Docente Universitário) University of Coimbra, Faculty of Pharmacy, Portugal
2003/02/22 - Atual Professor Auxiliar (Docente Universitário) Universidade de Coimbra Faculdade de Farmácia, Portugal
2016 - 2018 Professor Auxiliar (Docente Universitário) Universidade de Coimbra, Portugal
2013 - 2016 Professor Auxiliar (Docente Universitário) Universidade de Coimbra Faculdade de Farmácia, Portugal
2013 - 2016 Professor Auxiliar (Docente Universitário) Universidade de Coimbra Faculdade de Farmácia, Portugal
2003/02 - 2008/02 Professor Auxiliar (Docente Universitário) Universidade de Coimbra, Portugal
1996/01 - 2003/02 Assistente (Docente Universitário) Universidade de Coimbra, Portugal
1998/02 - 2001/04 Assistente (Docente Universitário) Universite de Lausanne, Suiça
1993/03 - 1996/01 Assistente Estagiário (Docente Universitário) Universidade de Coimbra, Portugal

Cargos e Funções

Categoria Profissional
Instituição de acolhimento
2020/10/01 - Atual President of CNC Universidade de Coimbra, Portugal
CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Portugal
2014/07/01 - Atual Vice-Presidente Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
2017 - 2018 Coordenação ou direção de centro de investigação, departamento ou equivalente Universidade de Coimbra, Portugal
2013 - 2016 Conselho científico/técnico-científico ou orgão correspondente Universidade de Coimbra Faculdade de Farmácia, Portugal
2013 - 2016 Conselho científico/técnico-científico ou orgão correspondente Universidade de Coimbra Faculdade de Farmácia, Portugal
1991/09/01 - 1993/05/31 Dirigente de laboratório, instituto, museu, centro ou observatório Laboratórios Delta - Rotta Research Group , Portugal
Laboratórios Delta - Rotta Research Group , Portugal


Categoria Profissional
Instituição de acolhimento
2008/02/22 - Atual Nomeação definitiva | Tenure Universidade de Coimbra Faculdade de Farmácia, Portugal


Designação Financiadores
2013 - 2016/12 Machado-Joseph-Disease, protein aggregation, protein degradation, stem cell biology, proteostasis, neurodegeneration
Provided by PTCRIS: 132829PRJ
Fundação para a Ciência e a Tecnologia
2005 - 2008/08 Transcription regulation by FK506 and BDNF control mitochondrial dependent cell death - a protective role in Huntington's disease
Provided by PTCRIS: 57310PRJ
Fundação para a Ciência e a Tecnologia


Artigo em revista
  1. Ana Vasconcelos-Ferreira; Sara Carmo-Silva; José Miguel Codêsso; Patrick Silva; Alberto Rolim Muro Martinez; Marcondes Cavalcante França Jr; Clévio Nóbrega; et al. "The autophagy-enhancing drug carbamazepine improves neuropathology and motor impairment in mouse models of Machado–Joseph disease". Neuropathology and Applied Neurobiology (2022): https://doi.org/10.1111/nan.12763.
  2. Holger Hengel; Peter Martus; Jennifer Faber; Hector Garcia-Moreno; Nita Solanky; Paola Giunti; Thomas Klockgether; et al. "Characterization of Lifestyle in Spinocerebellar Ataxia Type 3 and Association with Disease Severity". Movement Disorders (2022): https://doi.org/10.1002/mds.28844.
  3. Ana Teresa Simões; Vítor Carmona; Joana Duarte-Neves; Janete Cunha-Santos; Luís Pereira de Almeida. "Identification of the calpain-generated toxic fragment of ataxin-3 protein provides new avenues for therapy of Machado–Joseph disease| Spinocerebellar ataxia type 3". Neuropathology and Applied Neurobiology (2022): https://doi.org/10.1111/nan.12748.
  4. Vasconcelos-Ferreira, A.; Martins, I.M.; Lobo, D.; Pereira, D.; Lopes, M.M.; Faro, R.; Lopes, S.M.; et al. "ULK overexpression mitigates motor deficits and neuropathology in mouse models of Machado-Joseph disease". Molecular Therapy 30 1 (2022): 370-387. http://www.scopus.com/inward/record.url?eid=2-s2.0-85115030983&partnerID=MN8TOARS.
  5. Rufino-Ramos, D.; Lule, S.; Mahjoum, S.; Ughetto, S.; Cristopher Bragg, D.; Pereira de Almeida, L.; Breakefield, X.O.; Breyne, K.. "Using genetically modified extracellular vesicles as a non-invasive strategy to evaluate brain-specific cargo". Biomaterials 281 (2022): http://www.scopus.com/inward/record.url?eid=2-s2.0-85122652441&partnerID=MN8TOARS.
  6. Ana S. Neto; Patrícia Pereira; Ana C. Fonseca; Carla Dias; Mariana C. Almeida; Inês Barros; Catarina O. Miranda; et al. "Highly Porous Composite Scaffolds Endowed with Antibacterial Activity for Multifunctional Grafts in Bone Repair". Polymers (2021): https://doi.org/10.3390/polym13244378.
  7. Shadi Mahjoum; David Rufino-Ramos; Luís Pereira de Almeida; Marike L. D. Broekman; Xandra O. Breakefield; Thomas S. van Solinge; Mahjoum, Shadi; et al. "Living Proof of Activity of Extracellular Vesicles in the Central Nervous System". International Journal of Molecular Sciences 22 14 (2021): 7294-7294. https://doi.org/10.3390/ijms22147294.
  8. Barros, I.; Silva, A.; de Almeida, L.P.; Miranda, C.O.. "Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy". Cytokine and Growth Factor Reviews (2021): http://www.scopus.com/inward/record.url?eid=2-s2.0-85098642605&partnerID=MN8TOARS.
  9. Duarte-Neves, J.; Cavadas, C.; Pereira de Almeida, L.. "Neuropeptide Y (NPY) intranasal delivery alleviates Machado–Joseph disease". Scientific Reports 11 1 (2021): http://www.scopus.com/inward/record.url?eid=2-s2.0-85100703911&partnerID=MN8TOARS.
  10. Klionsky, D.J.; Abdel-Aziz, A.K.; Abdelfatah, S.; Abdellatif, M.; Abdoli, A.; Abel, S.; Abeliovich, H.; et al. "Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)". Autophagy (2021): http://www.scopus.com/inward/record.url?eid=2-s2.0-85102619204&partnerID=MN8TOARS.
  11. Hübener-Schmid, J.; Kuhlbrodt, K.; Peladan, J.; Faber, J.; Santana, M.M.; Hengel, H.; Jacobi, H.; et al. "Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood". Movement Disorders (2021): http://www.scopus.com/inward/record.url?eid=2-s2.0-85113149446&partnerID=MN8TOARS.
  12. Marcelo, A.; Afonso, I.T.; Afonso-Reis, R.; Brito, D.V.C.; Costa, R.G.; Rosa, A.; Alves-Cruzeiro, J.; et al. "Autophagy in Spinocerebellar ataxia type 2, a dysregulated pathway, and a target for therapy". Cell Death and Disease 12 12 (2021): 8-28. http://www.scopus.com/inward/record.url?eid=2-s2.0-85120082938&partnerID=MN8TOARS.
  13. Walter, J.; Bolognin, S.; Poovathingal, S.K.; Magni, S.; Gérard, D.; Antony, P.M.A.; Nickels, S.L.; et al. "The Parkinson's-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1". Cell Reports 37 3 (2021): http://www.scopus.com/inward/record.url?eid=2-s2.0-85117275453&partnerID=MN8TOARS.
  14. Aguiar, S.I.; Dias, J.N.R.; André, A.S.; Silva, M.L.; Martins, D.; Carrapiço, B.; Castanho, M.; et al. "Highly specific blood-brain barrier transmigrating single-domain antibodies selected by an in vivo phage display screening". Pharmaceutics 13 10 (2021): http://www.scopus.com/inward/record.url?eid=2-s2.0-85116780736&partnerID=MN8TOARS.
  15. Moreira, R.; Mendonça, L.S.; de Almeida, L.P.. "Extracellular vesicles physiological role and the particular case of disease-spreading mechanisms in polyglutamine diseases". International Journal of Molecular Sciences 22 22 (2021): http://www.scopus.com/inward/record.url?eid=2-s2.0-85118955937&partnerID=MN8TOARS.
  16. Marcelo, A.; Koppenol, R.; de Almeida, L.P.; Matos, C.A.; Nóbrega, C.. "Stress granules, RNA-binding proteins and polyglutamine diseases: too much aggregation?". Cell Death and Disease 12 6 (2021): http://www.scopus.com/inward/record.url?eid=2-s2.0-85107594482&partnerID=MN8TOARS.
  17. Diana Duarte Lobo; Rui Jorge Nobre; Catarina Oliveira Miranda; Dina Pereira; João Castelhano; José Sereno; Arnulf Koeppen; Miguel Castelo-Branco; Luís Pereira de Almeida. "The blood-brain barrier is disrupted in Machado-Joseph disease/spinocerebellar ataxia type 3: evidence from transgenic mice and human post-mortem samples". Acta Neuropathologica Communications (2020): https://doi.org/10.1186/s40478-020-00955-0.
  18. Laetitia S. Gaspar; Magda M. Santana; Carina Henriques; Maria M. Pinto; Teresa M. Ribeiro-Rodrigues; Henrique Girão; Rui Jorge Nobre; Luís Pereira de Almeida. "Simple and Fast SEC-Based Protocol to Isolate Human Plasma-Derived Extracellular Vesicles for Transcriptional Research". Molecular Therapy - Methods & Clinical Development (2020): https://doi.org/10.1016/j.omtm.2020.07.012.
  19. Santana, Magda M.; Paixão, Susana; Cunha-Santos, Janete; Silva, Teresa Pereira; Trevino-Garcia, Allyson; Gaspar, Laetitia S.; Nóbrega, Clévio; et al. "Trehalose alleviates the phenotype of Machado–Joseph disease mouse models". Journal of Translational Medicine 18 1 (2020): http://dx.doi.org/10.1186/s12967-020-02302-2.
  20. Lopes, Sara Monteiro; Faro, Rosário; Lopes, Miguel Monteiro; Onofre, Isabel; Mendonça, Nuno; Ribeiro, Joana; Januário, Cristina; Nobre, Rui Jorge; Pereira de Almeida, Luís. "Protocol for the Characterization of the CAG Tract and Flanking Polymorphisms in Machado-Joseph Disease: Impact on Diagnosis and Development of Gene-Based Therapies". The Journal of Molecular Diagnostics (2020): http://dx.doi.org/10.1016/j.jmoldx.2020.03.003.
  21. Barros-Viegas, Ana Teresa; Carmona, Vítor; Ferreiro, Elisabete; Guedes, Joana; Cardoso, Ana Maria; Cunha, Pedro; Pereira de Almeida, Luís; et al. "miRNA-31 Improves Cognition and Abolishes Amyloid-ß Pathology by Targeting APP and BACE1 in an Animal Model of Alzheimer’s Disease". Molecular Therapy - Nucleic Acids 19 (2020): 1219-1236. http://dx.doi.org/10.1016/j.omtn.2020.01.010.
  22. Aveleira, Célia A; Ferreira-Marques, Marisa; Cortes, Luísa; Valero, Jorge; Pereira, Dina; Pereira de Almeida, Luís; Cavadas, Cláudia. "Neuropeptide Y Enhances Progerin Clearance and Ameliorates the Senescent Phenotype of Human Hutchinson-Gilford Progeria Syndrome Cells". The Journals of Gerontology: Series A (2020): http://dx.doi.org/10.1093/gerona/glz280.
  23. Wilke, C.; Haas, E.; Reetz, K.; Faber, J.; Garcia-Moreno, H.; Santana, M.M.; van de Warrenburg, B.; et al. "Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice". EMBO Molecular Medicine 12 7 (2020): http://www.scopus.com/inward/record.url?eid=2-s2.0-85086096828&partnerID=MN8TOARS.
  24. Barros, I.; Marcelo, A.; Silva, T.P.; Barata, J.; Rufino-Ramos, D.; Pereira de Almeida, L.; Miranda, C.O.. "Mesenchymal Stromal Cells’ Therapy for Polyglutamine Disorders: Where Do We Stand and Where Should We Go?". Frontiers in Cellular Neuroscience 14 (2020): http://www.scopus.com/inward/record.url?eid=2-s2.0-85093862610&partnerID=MN8TOARS.
  25. Lopes, C.; Tang, Y.; Anjo, S.I.; Manadas, B.; Onofre, I.; de Almeida, L.P.; Daley, G.Q.; Schlaeger, T.M.; Rego, A.C.C.. "Mitochondrial and Redox Modifications in Huntington Disease Induced Pluripotent Stem Cells Rescued by CRISPR/Cas9 CAGs Targeting". Frontiers in Cell and Developmental Biology 8 (2020): http://www.scopus.com/inward/record.url?eid=2-s2.0-85092059116&partnerID=MN8TOARS.
  26. Henriques, Daniel; Moreira, Ricardo; Schwamborn, Jens; Pereira de Almeida, Luís; Mendonça, Liliana S.. "Successes and Hurdles in Stem Cells Application and Production for Brain Transplantation". Frontiers in Neuroscience 13 (2019): http://dx.doi.org/10.3389/fnins.2019.01194.
  27. Ana C Silva; Diana D Lobo; Inês M Martins; Sara M Lopes; Carina Henriques; Sónia P Duarte; Jean-Cosme Dodart; Rui Jorge Nobre; Luis Pereira de Almeida. "Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders". Brain (2019): https://doi.org/10.1093/brain/awz328.
  28. Almeida, Luis. "RNA Interference Therapy for Machado-Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3.". Human gene therapy (2019): https://doi.org/10.1089/hum.2018.157.
  29. Liliana S Mendonça; Clévio Nóbrega; Silvia Tavino; Maximilian Brinkhaus; Carlos Matos; Sandra Tomé; Ricardo Moreira; et al. "Ibuprofen enhances synaptic function and neural progenitors proliferation markers and improves neuropathology and motor coordination in Machado-Joseph disease models". Human Molecular Genetics (2019): https://doi.org/10.1093/hmg/ddz097.
  30. Almeida, Luis. "Neural Stem Cells of Parkinson's Disease Patients Exhibit Aberrant Mitochondrial Morphology and Functionality.". Stem cell reports (2019): http://europepmc.org/articles/PMC6522948.
  31. Nóbrega, Clévio; Codesso, Jose Miguel; Mendonca, Liliana; de Almeida, Luis Pereira. "RNA interference therapy for Machado-Joseph disease: Long-term safety profile of lentiviral vectors encoding short hairpin RNAs targeting mutant ataxin-3". (2019): http://hdl.handle.net/10400.1/14340.
  32. Marcelo, Adriana; Brito, Filipa; Carmo-Silva, Sara; Matos, Carlos A.; Alves-Cruzeiro, Joao; Vasconcelos-Ferreira, Ana; Koppenol, Rebekah; et al. "Cordycepin activates autophagy through AMPK phosphorylation to reduce abnormalities in Machado-Joseph disease models". Human molecular genetics 28 1 (2019): 51-63. http://hdl.handle.net/10400.1/14482.
  33. Nóbrega, Clévio; Mendonca, Liliana; Marcelo, Adriana; Lamaziere, Antonin; Tome, Sandra; Despres, Gaetan; Matos, Carlos A; et al. "Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia". Acta Neuropathologica (2019): http://hdl.handle.net/10400.1/14197.
  34. Rodrigues, C.F.D.; Serrano, E.; Patrício, M.I.; Val, M.M.; Albuquerque, P.; Fonseca, J.; Gomes, C.M.F.; et al. "Stroma-derived IL-6, G-CSF and Activin-A mediated dedifferentiation of lung carcinoma cells into cancer stem cells". Scientific Reports 8 1 (2018): http://www.scopus.com/inward/record.url?eid=2-s2.0-85050990420&partnerID=MN8TOARS.
  35. Marques, A.P.; Cunha-Santos, J.; Leal, H.; Sousa-Ferreira, L.; Pereira de Almeida, L.; Cavadas, C.; Rosmaninho-Salgado, J.. "Dipeptidyl peptidase IV (DPP-IV) inhibition prevents fibrosis in adipose tissue of obese mice". Biochimica et Biophysica Acta - General Subjects 1862 3 (2018): 403-413. http://www.scopus.com/inward/record.url?eid=2-s2.0-85037668547&partnerID=MN8TOARS.
  36. Pólvora-Brandão, D.; Joaquim, M.; Godinho, I.; Aprile, D.; Álvaro, A.R.; Onofre, I.; Raposo, A.C.; et al. "Loss of hierarchical imprinting regulation at the Prader-Willi/Angelman syndrome locus in human iPSCs". Human molecular genetics 27 23 (2018): 3999-4011. http://www.scopus.com/inward/record.url?eid=2-s2.0-85056694837&partnerID=MN8TOARS.
  37. Oliveira Miranda, C.; Marcelo, A.; Silva, T.P.; Barata, J.; Vasconcelos-Ferreira, A.; Pereira, D.; Nóbrega, C.; et al. "Repeated Mesenchymal Stromal Cell Treatment Sustainably Alleviates Machado-Joseph Disease". Molecular Therapy (2018): http://www.scopus.com/inward/record.url?eid=2-s2.0-85050950218&partnerID=MN8TOARS.
  38. Gonçalves, N.; Simões, A.T.; Prediger, R.D.; Hirai, H.; Cunha, R.A.; Pereira de Almeida, L.. "Caffeine alleviates progressive motor deficits in a transgenic mouse model of spinocerebellar ataxia". Annals of Neurology 81 3 (2017): 407-418. http://www.scopus.com/inward/record.url?eid=2-s2.0-85013441188&partnerID=MN8TOARS.
  39. Rufino-Ramos, D.; Albuquerque, P.R.; Carmona, V.; Perfeito, R.; Nobre, R.J.; Pereira de Almeida, L.. "Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases". Journal of Controlled Release 262 (2017): 247-258. http://www.scopus.com/inward/record.url?eid=2-s2.0-85026758579&partnerID=MN8TOARS.
  40. Cristo, F.; Inácio, J.M.; Rosas, G.; Carreira, I.M.; Melo, J.B.; de Almeida, L.P.; Mendes, P.; et al. "Generation of human iPSC line from a patient with laterality defects and associated congenital heart anomalies carrying a DAND5 missense alteration". Stem Cell Research 25 (2017): 152-156. http://www.scopus.com/inward/record.url?eid=2-s2.0-85033403571&partnerID=MN8TOARS.
  41. Hachigian, L.J.; Carmona, V.; Fenster, R.J.; Kulicke, R.; Heilbut, A.; Sittler, A.; Pereira de Almeida, L.; et al. "Control of Huntington's Disease-Associated Phenotypes by the Striatum-Enriched Transcription Factor Foxp2". Cell Reports 21 10 (2017): 2688-2695. http://www.scopus.com/inward/record.url?eid=2-s2.0-85038085324&partnerID=MN8TOARS.
  42. Matos, C.A.; de Almeida, L.P.; Nóbrega, C.. "Proteolytic cleavage of polyglutamine disease-causing proteins: Revisiting the toxic fragment hypothesis". Current Pharmaceutical Design 23 5 (2017): 753-775. http://www.scopus.com/inward/record.url?eid=2-s2.0-85017122161&partnerID=MN8TOARS.
  1. Nóbrega, C.; Simões, A.T.; Duarte-Neves, J.; Duarte, S.; Vasconcelos-Ferreira, A.; Cunha-Santos, J.; Pereira, D.; et al. Molecular Mechanisms and Cellular Pathways Implicated in Machado-Joseph Disease Pathogenesis. 2018.
  2. Matos, C.A.; Carmona, V.; Vijayakumar, U.-G.; Lopes, S.; Albuquerque, P.; Conceição, M.; Nobre, R.J.; Nóbrega, C.; de Almeida, L.P.. Gene therapies for polyglutamine diseases. 2018.
  3. Mendonça, L.S.; Onofre, I.; Miranda, C.O.; Perfeito, R.; Nóbrega, C.; de Almeida, L.P.. Stem Cell-Based Therapies for Polyglutamine Diseases. 2018.
Tese / Dissertação
  1. Barros, Maria Inês Veiga de Almeida. "Assessing the putative role of mesenchymal stromal cells’ effectors in Machado-Joseph disease". Mestrado, 2019. http://hdl.handle.net/10316/86421.


Outra produção
  1. Polyglutamine disorders preface. 2018. Nóbrega, Clévio; Almeida, Luís Pereira de. http://hdl.handle.net/10400.1/11962.